RxDoctor Payments Data

Hannah Braden, APRN

Psychiatric/Mental Health · Knoxville, TNNPI 1265916241

Payments from drug & device makers

$3,595in general payments, 2019–2025

Across 183 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$978
  • Otsuka America Pharmaceutical, Inc.$719
  • Sunovion Pharmaceuticals Inc.$320
  • Teva Pharmaceuticals USA, Inc.$288
  • Neurocrine Biosciences, Inc.$258
  • Takeda Pharmaceuticals U.S.A., Inc.$205
  • plus $827 from 10 others

What the payments were for

  • Food & beverage$3,595100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,595 in reported general payments places this provider in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

See all psychiatric/mental health providers in Tennessee

Medicare billing

Part B allowed, 2024
$16,272
Medicare patients
21
Services billed
245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CaplytaLumateperone Tosylate36$68,926
VraylarCariprazine Hcl13$18,406
Asenapine Maleate13$1,782
Duloxetine Hcl84$1,750
Temazepam11$1,446
Buspirone Hcl46$523
Fluoxetine Hcl27$493
Aripiprazole27$491
Clonazepam68$439
Alprazolam ErAlprazolam13$379
Hydroxyzine Pamoate18$349
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine14$339
Divalproex Sodium23$332
Trazodone Hcl63$320
Sertraline Hcl68$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$146$68,92636 claims
AbbVieVraylar$978$18,40613 claims
Almatica Pharma LLCSertraline Hcl$36$30868 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,167 psychiatric/mental health providers in Tennessee.

Other psychiatric/mental health in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →